Compare · IRWD vs SYRS
IRWD vs SYRS
Side-by-side comparison of Ironwood Pharmaceuticals Inc. (IRWD) and Syros Pharmaceuticals Inc. (SYRS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRWD and SYRS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- IRWD is the larger of the two at $635.4M, about 5.3x SYRS ($119.6M).
- Over the past year, IRWD is up 403.8% and SYRS is up 0.0% - IRWD leads by 403.8 points.
- IRWD has hit the wire 2 times in the past 4 weeks while SYRS has been quiet.
- IRWD has more recent analyst coverage (14 ratings vs 1 for SYRS).
- Company
- Ironwood Pharmaceuticals Inc.
- Syros Pharmaceuticals Inc.
- Price
- $3.85-0.77%
- $0.12-6.03%
- Market cap
- $635.4M
- $119.6M
- 1M return
- +4.90%
- +0.00%
- 1Y return
- +403.79%
- +0.00%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2010
- 2016
- News (4w)
- 2
- 0
- Recent ratings
- 14
- 1
Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist, which is in pre-clinical development for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
Syros Pharmaceuticals Inc.
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are SY-1425, a selective retinoic acid receptor alpha agonist, which is in Phase II clinical trial for genomically defined subset of patients with acute myeloid leukemia and phase III clinical trial for patents with myelodysplastic syndrome; SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors; and SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia. It has target discovery, research collaboration, and option agreement with Incyte Corporation to identify therapeutic targets with a focus on myeloproliferative neoplasms; and a license agreement with TMRC Co. Ltd. for the development and commercialization of tamibarotene. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
Latest IRWD
- Ironwood Appoints Dr. Jeffrey Silber Chief Medical Officer and Head of Research and Drug Development; STARS-2 Trial Initiated in June and Is Now Actively Recruiting Patients
- PFO & PAO Silver Ronald sold $578,063 worth of shares (127,890 units at $4.52) as part of a pre-agreed trading plan, decreasing direct ownership by 29% to 313,680 units (SEC Form 4)
- Ironwood Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Director Shepard Jay was granted 63,481 shares, increasing direct ownership by 37% to 235,036 units (SEC Form 4)
- Director Kessler Marla L was granted 63,481 shares, increasing direct ownership by 38% to 229,364 units (SEC Form 4)
- Director Currie Mark G was granted 63,481 shares, increasing direct ownership by 10% to 676,900 units (SEC Form 4)
- Director Duane Jon R was granted 63,481 shares, increasing direct ownership by 33% to 253,820 units (SEC Form 4)
- Director Denner Alexander J was granted 67,546 shares, increasing direct ownership by 26% to 323,855 units (SEC Form 4)
- Director Mchugh Julie sold $80,460 worth of shares (21,571 units at $3.73) as part of a pre-agreed trading plan and was granted 63,481 shares, increasing direct ownership by 20% to 250,749 units (SEC Form 4)
- Director Moukheibir Catherine was granted 63,481 shares, increasing direct ownership by 54% to 181,425 units (SEC Form 4)
Latest SYRS
- Rege Nephro Acquires Tamibarotene-Related Assets from Syros Pharmaceuticals for U.S. Clinical Trials
- SEC Form 15-12G filed by Syros Pharmaceuticals Inc.
- SEC Form 144 filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.
- SEC Form EFFECT filed by Syros Pharmaceuticals Inc.